CLEVELAND, Jan. 31, 2022 /PRNewswire/ -- NovelMed Therapeutics announced today that its Investigational New Drug Application (IND) to initiate clinical trials of its NM8074 biologic has been cleared ...

C1q is the initiating component of the classical complement pathway and plays a critical role in activating macrophages and microglia through receptor-mediated signaling. Dysregulated C1q activity ...

iPierian Advances Monoclonal Antibody Drug Development Programs Targeting Tau Protein and the Complement System for the Treatment of Neurodegenerative Diseases SOUTH SAN FRANCISCO, Calif., May 21, ...

CLEVELAND, Sept. 25, 2013 /PRNewswire-USNewswire/ -- Today NovelMed Therapeutics announced preclinical study results for its lead compound in two models of AMD, a major cause of blindness affecting ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES, February 27, 2026 /EINPresswire.com/ — ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...